A novel sorbicillinoid compound as a potent anti‐inflammation agent through inducing NLRP3 protein degradation
British Journal of Pharmacology · 2023-08 · 180 (15) · 1930-1948
DOI: 10.1111/bph.16058 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 28.02.2023. Verfasst von Fangfang Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine and New Drug Research, International Cooperative La…. Hauptthemen laut MEDLINE: Colitis, NLR Family, Pyrin Domain-Containing 3 Protein. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, National Key Research and Development Program of China.
Abstract (Originalsprache)
Background and Purpose Chronic inflammation is pathogenic and contributes to human diseases, causing a significant threat to public health. The NLR family pyrin domain‐containing protein 3 (NLRP3) is the best‐characterized factor regulating inflammation. Therefore, targeting NLRP3 has the potential to treat inflammatory diseases and improve human health. Experimental Approach Lipopolysaccharide was used to induce inflammation in cell cultures. Lipopolysaccharide/ d ‐galactosamine and dextran sulfate sodium salt were used to induce acute liver inflammation and ulcerative colitis respectively in C57BL/6J mice. Western blotting, immunofluorescence, immunoprecipitation, quantitative PCR and enzyme‐linked immunosorbent assay (ELISA) were used to evaluate the activation of the inflammatory response in cell cultures and in mice. Key Results JNUTS013, a novel sorbicillinoid compound recently synthesized by us, significantly inhibited inflammation both in cell cultures and in mouse models. Mechanistically, JNUTS013 induced proteasome‐dependent degradation of NLRP3. Hence, it suppressed the formation of the NLRP3 inflammasome and the production of downstream inflammatory cytokines and chemokines. The inhibitory effect of JNUTS013 on NLRP3 protein expression was confirmed in mice. Importantly, JNUTS013 failed to ameliorate bowel inflammation in Nlrp3 ‐/‐ knockout mice, supporting NLRP3 as the biological target by which JNUTS013 inhibits inflammation. Further studies revealed critical chemical moieties of JNUTS013 required for inducing NLRP3 degradation. Conclusion and Implications This study identifies a novel compound JNUTS013 that inhibits inflammation through inducing NLRP3 protein degradation in vitro and in vivo , which not only supports the development of JNUTS013 as an anti‐inflammation agent but also creates a new way for the treatment of inflammation by chemically inducing NLRP3 degradation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine and New Drug Research, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative…
- Department of Pharmacology, Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
- The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang, China.
- The Marine Biomedical Research Institute of Guangdong Zhanjiang, Zhanjiang, China.
ORCID-Profile: Fangfang Wang, Lianxiang Luo, Jinshan Tang, Youwei Zhang
Förderung
- NCI NIH HHS
- National Key Research and Development Program of China
Zitieren
APA
Wang, F., Zhang, M., Yuan, M., Xia, Z., Yang, F., Zhang, S., Lin, T., Luo, L., Tang, J., & Zhang, Y. (2023). A novel sorbicillinoid compound as a potent anti‐inflammation agent through inducing NLRP3 protein degradation. British Journal of Pharmacology, 180(15), 1930-1948. https://doi.org/10.1111/bph.16058
Vancouver
Wang F, Zhang M, Yuan M, Xia Z, Yang F, Zhang S, et al. A novel sorbicillinoid compound as a potent anti‐inflammation agent through inducing NLRP3 protein degradation. British Journal of Pharmacology. 2023;180(15):1930-1948. doi:10.1111/bph.16058
BibTeX
@article{Wang2023,
author = {Wang, Fangfang and Zhang, Meng and Yuan, Meng and Xia, Zixuan and Yang, Fengge and Zhang, Sihao and Lin, Tengyu and Luo, Lianxiang and Tang, Jinshan and Zhang, Youwei},
title = {A novel sorbicillinoid compound as a potent anti‐inflammation agent through inducing NLRP3 protein degradation},
journal = {British Journal of Pharmacology},
year = {2023},
volume = {180},
number = {15},
pages = {1930--1948},
doi = {10.1111/bph.16058}
}
EUVIMED